Alnylam Pharmaceuticals
Financials
Valuation Metrics
Alnylam Pharmaceuticals's Market Cap is $29.42B. At end of 2025 it was $52.58B. Ranked #494 of 3,111 in US market (top 16%), #145 of 1,445 on NASDAQ (top 10%), #33 of 206 in Health Care Equipment & Services (top 16%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $29.42B | US#494/3,111 Sec#33/206 |
| Revenue | $4.80B | US#995/3,111 Sec#54/206 |
| Net Income | $808M | US#742/3,111 Sec#43/206 |
| Total Assets | $5.56B | US#1,429/3,111 Sec#70/206 |
| Net Assets | $1.35B | US#1,731/3,111 Sec#91/206 |
| Employees | 2,500 | US#1,056/3,111 Sec#88/206 |
| Value | ||
| P/E | 36.41x | US#1,832/3,111 Sec#90/206 |
| P/B | 21.73x | US#2,864/3,111 Sec#192/206 |
| P/S | 6.12x | US#2,448/3,111 Sec#172/206 |
| EV/EBITDA | 25.19x | US#2,164/3,111 Sec#114/206 |
| FCF Yield | 1.84% | US#1,893/3,111 Sec#118/206 |
| Profitability | ||
| ROE | 59.67% | US#106/3,111 Sec#7/206 |
| ROA | 14.54% | US#368/3,111 Sec#19/206 |
| Op. Margin | 20.81% | US#1,074/3,111 Sec#36/206 |
| Revenue Growth | 66.86% | US#154/3,111 Sec#4/206 |
| Financial Health | ||
| Debt Ratio | 310.51% | US#2,266/3,111 Sec#180/206 |
| Total Debt | $1.27B | US#1,379/3,111 Sec#74/206 |
| FCF | $543M | US#761/3,111 Sec#47/206 |
| Cash | $1.71B | US#481/3,111 Sec#28/206 |
| Current Ratio | 3.05x | US#766/3,111 Sec#80/206 |
| Net Debt/EBITDA | -0.38x | US#451/3,111 Sec#33/206 |
| Performance | ||
| 1Y Return | -45.16% | US#2,931/3,111 Sec#191/206 |
| 1M Return | -29.55% | US#3,039/3,111 Sec#203/206 |
| From 52W High | -55.54% | US#2,893/3,111 Sec#191/206 |
| 1Y MDD | -58.17% | US#2,674/3,111 Sec#168/206 |
| Trading | ||
| Volume | 2,798,971 shares | US#403/3,111 Sec#16/206 |
| Trading Value | $605M | US#97/3,111 Sec#4/206 |
| Per Share | ||
| EPS | $2.37 | US#1,150/3,111 Sec#60/206 |
| BPS | $5.97 | US#2,140/3,111 Sec#136/206 |
Company Info
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.